VIMPAT (lacosamide) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older.
VIMPAT (lacosamide) injection for intravenous use is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older when oral administration is temporarily not feasible.
DOSAGE AND ADMINISTRATION
VIMPAT may be taken with or without food.
When using VIMPAT oral solution, it is recommended that a calibrated measuring device be obtained and used. A household teaspoon or tablespoon is not an adequate measuring device. Healthcare providers should recommend a device that can measure and deliver the prescribed dose accurately, and provide instructions for measuring the dosage.
VIMPAT can be initiated with either oral or intravenous administration. The initial dose should be 5 0 mg twice daily (100 mg per day). VIMPAT can be increased at weekly intervals by 100 mg/day given as two divided doses up to the recommended maintenance dose of 200 to 400 mg/day, based on individual patient response and tolerability. In clinical trials, the 600 mg daily dose was not more effective than the 400 mg daily dose, and w as associated with a substantially higher rate of adverse reactions. [see Clinical Studies]
Switching from Oral to Intravenous Dosing
When switching from oral VIMPAT, the initial total daily intravenous dosage of VIMPAT should be equivalent to the total daily dosage and frequency of oral VIMPAT and should be infused intravenously over a period of 30 to 60 minutes. There is experience with twice daily intravenous infusion for up to 5 days.
Switching from Intravenous to Oral Dosing
At the end of the intravenous treatment period, the patient may be switched to VIMPAT oral administration at the equivalent daily dosage and frequency of the intravenous administration.
Compatibility and Stability
VIMPAT injection can be administered intravenously without further dilution or may be mixed with diluents. VIMPAT injection was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in glass or polyvinyl chloride (PVC) bags at ambient room temperature 15-30°C (5 9-86°F).
Sodium Chloride Injection 0.9% (w/v)
Dextrose Injection 5% (w/v)
Lactated Ringer's Injection
The stability of VIMPAT injection in other infusion solutions has not been evaluated. Product with particulate matter or discoloration should not be used.
Any unused portion of VIMPAT injection should be discarded.
Patients with Renal Impairment
No dose adjustment is necessary in patients with mild to moderate renal impairment. A maximum dose of 300 mg/day VIMPAT is recommended for patients with severe renal impairment [creatinine clearance (CLCR) ≤ 30mL/min] and in patients with end stage renal disease. VIMPAT is effectively removed from plasma by hemodialysis. Following a 4-hour hemodialysis treatment, dosage supplementation of up to 50% should be considered. In all renally impaired patients, the dose titration should be performed with caution. [see Use in Specific Populations]
Patients with Hepatic Impairment
The dose titration should be performed with caution in patients with hepatic impairment. A maximum dose of 300 mg/day is recommended for patients with mild or moderate hepatic impairment.
VIMPAT use is not recommended in patients with severe hepatic impairment [see Use In Specific Populations].
Dosage Forms And Strengths
50 mg (pink), 100 mg (dark yellow), 150 mg (salmon), and 200 mg (blue) film-coated tablets
200 mg/20mL injection
10 mg/mL oral solution
Storage And Handling
VIMPAT (lacosamide) Tablets 50 mg are pink, oval, film-coated tablets debossed with “SP” on one side and “50” on the other. They are supplied as follows:
Bottles of 60 NDC 0131-2477-35
VIMPAT (lacosamide) Tablets 100 mg are d ark yellow, oval, film-coated tablets debossed with “SP” on one side and “100” on the other. They are supplied as follows:
Bottles of 60 NDC 0131-2478-35
VIMPAT (lacosamide) Tablets 150 mg are salmon, oval, film-coated tablets debossed with “SP” on one side and “150” on the other. They are supplied as follows:
Bottles of 60 NDC 0131 -2479-35
VIMPAT (lacosamide) Tablets 200 mg are blue, oval, film-coated tab lets debossed with “SP” on one side and “200” on the other. They are supplied as follows:
Bottles of 60 NDC 0131-2480-35
VIMPAT (lacosami e) injection 200 mg/2d 0 mL is a clear, colorless sterile solution supplied in 20 mL colorless single-use glass vials.
200 mg/20 mL vial in cartons of 10 vials NDC 0131-1810-67
VIMPAT (lacosamide) oral solution 10 mg/mL is a clear, colorles s to yellow or yellow-brown, strawberry-flavored liquid. It is supplied in PET bottles as follows:
465 mL bottles NDC 0131-5410-70
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature].
Do not freeze Vimpat injection or oral solution. Discard any unused Vimpat oral solution remaining after seven (7) weeks of first opening the bottle.
Manufactured for UCB, Inc. Smyrna, GA 30080. Issued 04/2013
Last reviewed on RxList: 4/29/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Vimpat Information
Vimpat - User Reviews
Vimpat User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find tips and treatments to control seizures.